Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MGX

Metagenomi Inc.

May 13 • 04:00PM ET

6.55

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF VTI SCHA

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	49.54%	Shs Outstand	37.47M	Perf Week	1.24%
Market Cap	245.43M	Forward P/E	-	EPS next Y	-2.75	Insider Trans	5.10%	Shs Float	18.91M	Perf Month	-26.90%
Income	-	PEG	-	EPS next Q	-0.84	Inst Own	2.02%	Short Float	3.76%	Perf Quarter	-41.88%
Sales	-	P/S	-	EPS this Y	85.37%	Inst Trans	-	Short Ratio	4.15	Perf Half Y	-
Book/sh	-3.62	P/B	-	EPS next Y	6.19%	ROA	-	Short Interest	0.71M	Perf Year	-
Cash/sh	7.24	P/C	0.91	EPS next 5Y	-	ROE	-	52W Range	5.50 - 12.74	Perf YTD	-36.47%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-48.59%	Beta	-
Dividend TTM	-	Quick Ratio	4.04	Sales past 5Y	3569.20%	Gross Margin	-	52W Low	19.09%	ATR (14)	0.71
Dividend Ex-Date	-	Current Ratio	4.04	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	37.15	Volatility	7.78% 10.34%
Employees	236	Debt/Eq	0.22	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.29	Target Price	17.00
Option/Short	No / Yes	LT Debt/Eq	0.21	EPS Q/Q	-	Payout	-	Rel Volume	0.11	Prev Close	6.55
Sales Surprise	6.89%	EPS Surprise	16.72%	Sales Q/Q	-	Earnings	Mar 28 BMO	Avg Volume	171.12K	Price	6.55
SMA20	-7.91%	SMA50	-30.14%	SMA200	-33.74%	Trades		Volume	18,109	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
May-07-24	Initiated	H.C. Wainwright	Buy	$10
May-02-24	Downgrade	JP Morgan	Overweight → Neutral	$16 → $6
Mar-05-24	Initiated	Wells Fargo	Overweight	$25
Mar-05-24	Initiated	TD Cowen	Outperform
Mar-05-24	Initiated	JP Morgan	Overweight	$16
Mar-05-24	Initiated	Jefferies	Buy	$23
Mar-05-24	Initiated	Chardan Capital Markets	Buy	$21
Mar-05-24	Initiated	BMO Capital Markets	Outperform	$22

May-04-24 10:49AM	Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-02-24 06:04AM	3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire (InvestorPlace) -12.36%
May-01-24 04:00PM	Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems (GlobeNewswire)
01:53PM	Moderna exits gene editing deal worth up to $3B biobucks, leaving Metagenomi in the spotlight (FierceBiotech.com)
Apr-08-24 08:00AM	Metagenomi to Present at Upcoming Scientific Meetings (GlobeNewswire)
09:16AM	Loading…
Mar-27-24 09:16AM	Metagenomi Reports Business Updates and Full Year 2023 Financial Results (GlobeNewswire)
Feb-29-24 04:30PM	Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference (GlobeNewswire)
Feb-13-24 04:35PM	Metagenomi Announces Closing of Initial Public Offering (GlobeNewswire)
Feb-08-24 10:16PM	Metagenomi Announces Pricing of Initial Public Offering (GlobeNewswire)

Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit-ing toolbox, ther-a-peu-tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novo Holdings A/S	10% Owner	Feb 13 '24	Buy	15.00	800,000	12,000,000	1,739,175	Feb 15 08:38 PM
Novo Holdings A/S	10% Owner	Feb 09 '24	Buy	10.25	100,000	1,025,000	100,000	Feb 15 08:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MGX

Metagenomi Inc.

Upgrade your FINVIZ experience